- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
연구 개요
상세 설명
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Hubert Chen, MD
- 전화번호: 8587044660
- 이메일: clinicaltrials@vikingtherapeutics.com
연구 장소
-
-
Arizona
-
Tucson, Arizona, 미국, 85741
- 모병
- Viking Clinical Site #2020
-
연락하다:
- 전화번호: 520-333-4515
-
-
California
-
Lake Forest, California, 미국, 92630
- 모병
- Viking Clinical Site #2015
-
연락하다:
- 전화번호: 714-550-9990
-
-
Florida
-
Ocoee, Florida, 미국, 34761
- 모병
- Viking Clinical Site #2059
-
연락하다:
- 전화번호: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Viking Clinical Site #2013
-
연락하다:
- 전화번호: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, 미국, 47714
- 모병
- Viking Clinical Site #2001
-
연락하다:
- 전화번호: 812-477-2760
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Viking Clinical Site #2046
-
연락하다:
- 전화번호: 504-336-2667
-
Valparaiso, Indiana, 미국, 46383
- 모병
- Viking Clinical Site #2009
-
연락하다:
- 전화번호: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, 미국, 55423
- 모병
- Viking Clinical Site #2004
-
연락하다:
- 전화번호: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39206
- 모병
- Viking Clinical Site #2029
-
연락하다:
- 전화번호: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, 미국, 65807
- 모병
- Viking Clinical Site #2028
-
연락하다:
- 전화번호: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87107
- 모병
- Viking Clinical Site #2052
-
연락하다:
- 전화번호: 505-243-1627
-
-
New York
-
Binghamton, New York, 미국, 13905
- 모병
- Viking Clinical Site #2039
-
연락하다:
- 전화번호: 607-800-5777
-
-
Oregon
-
Medford, Oregon, 미국, 97504
- 모병
- Viking Clinical Site #2023
-
연락하다:
- 전화번호: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, 미국, 02818
- 모병
- Viking Clinical Site #2002
-
연락하다:
- 전화번호: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29407
- 모병
- Viking Clinical Site #2044
-
연락하다:
- 전화번호: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, 미국, 37075
- 모병
- Viking Clinical Site #2030
-
연락하다:
- 전화번호: 504-339-0917
-
-
Texas
-
Abilene, Texas, 미국, 79606
- 모병
- Viking Clinical Site #2031
-
연락하다:
- 전화번호: 325-400-1150
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Viking Clinical Site #2011
-
연락하다:
- 전화번호: 206-536-3030
-
Spokane, Washington, 미국, 99218
- 모병
- Viking Clinical Site #2042
-
연락하다:
- 전화번호: 509-505-6227
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
실험적: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
실험적: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
실험적: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
기간: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .